Enveda completes Phase 1 of ENV-308, an exercise-mimetic aimed at weight maintenance
A small Phase 1 safety study of Enveda's experimental exercise-mimetic ENV-308 cleared with no serious adverse events, but there are still no human weight or muscle data.
Enveda Biosciences has completed a Phase 1 study of ENV-308, an experimental weight-maintenance drug designed to mimic the effects of exercise, and said it is moving the molecule into Phase 2 [1]. The trial enrolled 88 healthy adults. The company reported no serious adverse events, and no participants discontinued or needed a dose interruption [1]. ENV-308 is not approved for any use, and no human weight-loss results have been reported for it [1].
What the study did and did not measure
Phase 1 tested safety and tolerability, not weight loss [1]. That means the trial was not set up to answer whether ENV-308 helps anyone hold onto weight loss or changes body composition. The lean-mass claims attached to the drug come from preclinical work, not from people [1].
What the drug is
ENV-308 was found using the company's machine-learning discovery platform, according to Enveda [1]. The molecule mimics Lac-Phe, a hormone released during intense exercise and after meals [1]. Enveda is positioning it as maintenance therapy against weight regain after a person stops taking a GLP-1 medication [1].
The company has not reported how ENV-308 is given, how often it is dosed, or what a Phase 2 study would look like. Those details are not yet known.
Why it matters for patients
Weight regain after stopping a GLP-1 is a common practical problem for people who take these drugs, and the current options for managing it are limited to staying on medication, switching medications, or returning to diet and activity changes. A drug designed specifically for maintenance, rather than for initial weight loss, would be a different kind of product from Ozempic, Wegovy, Mounjaro or Zepbound.
That said, ENV-308 is far from being one. Safety results in 88 healthy adults do not show whether a drug works, and they do not cover long-term use or use in people who have obesity along with other conditions. Because Phase 1 did not measure weight, there is no human evidence yet that ENV-308 prevents regain. Readers weighing this news against approved options should note that no efficacy data in people have been reported, and no price, insurance coverage or availability information exists.
ENV-308 is not the only early-stage bet on preserving muscle during weight loss. On August 24, Hanmi Pharmaceutical announced an exclusive licensing agreement with Genentech, part of the Roche Group, for HM17321, a clinical-stage obesity candidate: 190 million dollars upfront and up to roughly 2.3 billion dollars including development, regulatory and commercial milestones plus tiered royalties [1]. HM17321 is a urocortin-2 analog that activates the CRFR2 receptor, which puts it outside the incretin pathway that GLP-1 drugs use [1]. Its stated goal is weight loss while lean body mass is preserved, but it is only in Phase 1, with no measured human efficacy data, and its lean-mass claim rests on preclinical work so far [1]. Roche now holds two separate non-incretin, muscle-sparing programs, HM17321 and the amylin analog petrelintide it co-develops with Zealand Pharma [1].
What happens next
Enveda says it is moving ENV-308 to Phase 2, but has not reported a start date, a size, or an endpoint for that study [1]. Hanmi will finish the Phase 1 study of HM17321 and Genentech takes over from Phase 2; no dates have been given [1]. A Phase 2 study of petrelintide combined with enicepatide is expected to start in the second half of 2026 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.